Higher Dose of Fulvestrant Associated With Improved Survival in Advanced Breast Cancer
Ben Leach | December 05, 2012
Postmenopausal women with advanced estrogen receptor–positive breast cancer lived longer when they received a 500-mg dose of fulvestrant as compared with a 250-mg dose.
New data from the Netherlands suggest that young patients who undergo post-lumpectomy radiotherapy using tangential fields have an increased risk of cancer arising in the other breast.
Sentinel lymph node surgery may provide a less-invasive alternative to axillary lymph node dissection for nodal staging in node-positive breast cancer.
